Abstract. The aim of this study was to evaluate whether fast trabecular bone loss in osteoporotic and osteopenic patients can effectively be treated with active vitamin D metabolites. Thirty-one osteoporotic and osteopenic patients were monitored between 4 and 22 months before and between 8 and 18 months during the treatment. Fast bone losers were designated as osteoporotic or osteopenic patients with a loss of trabecular bone density in the radius of 3% or more calculated for 1 year. For this differentiation, the high precise peripheral quantitative computed tomography system (DENSISCAN 1000) was used (reproducability 0.3% in mixed collectives). The pretreatment loss and the "gain" under treatment with active vitamin D metabolites was calculated for 1 year. The treatment consisted of either 0.5 flg calcitriol daily or 1 flg of alfacalcidol daily. Before treatment, the trabecular bone loss in the radius/year was -6.6 ± 0.5% (mean ± SEM). After treatment with vitamin D metabolites, the trabecular bone gain in the radius/year was 0.01 ± 0.6% (mean ± SEM). The difference was highly significant (P < 0.001). In contrast to this, the loss of cortical bone density before treatment was -1.8 ± 0.3% (mean ± SEM) and the reduced loss after treatment -0.2 ± 0.4% (mean ± SEM), both values calculated for I year. This difference was less significant (P < 0.05). This study shows that the treatment with active vitamin D metabolites is very effective in slowing fast trabecular bone loss in osteoporotic and osteopenic patients.
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In postmenopausal and senile osteoporosis, reduced calcium absorption is often reported. Pathophysiologically, a disorder in the vitamin D metabolism as cause can be postulated, although it is of a different character. For both groups a lower concentration of 1,25(OHhD 3 in the serum, a decrease of the amount of 1,25(OHhD3 receptors, and a disorder of the active calcium absorption in the intestine is known. For the postmenopausal osteoporosis there is a low parathyroid hormone (PTH) level and an additional deficit in the activation of the PTH-induced 1,25(OHhD3 synthesis. For the senile osteoporosis, in addition to the above, there is a lack of vitamin D uptake and an increase in the Correspondence to: M. A. Dambacher amount of cells in the parathyroidea, with a higher level of PTH in the serum [1] .
Vitamin D metabolites have proved to be effective in preventing osteoporosis by increasing low mineral density [2] and decreasing fracture rates [3] [4] [5] while showing a low toxicity; the incidence of hypercalcemia is <1 % [6] . The prevention of bone loss has been shown to be due to restoration to a positive calcium balance due to a correction of calcium malabsorption [7] . Furthermore, it has been reported that treatment with alfacalcidol improves the myopathy associated with the bone loss of aging [8] and should reduce the tendency to fall and the risk of osteoporotic fractures.
Until now anabolic substances like fluorides were used for the tailored treatment of osteoporosis in slow bone losers (loss of trabecular bone density in the radius of less than 3% calculated for 1 year). Fast bone losers were treated with antiresorptive agents like estrogens, calcitonin, and bisphosphonates [9] . The aim of the present study was to determine whether the treatment with the active vitamin D metabolites calcitriol and alfacalcidol can prevent a fast trabecular bone loss and could thus be considered as antiresorptive agents.
Patient and Methods

Treatment Protocol
Thirty-one postmenopausal female patients aged 47-82 years were admitted to the study. The mean age was 68.1 ± 8.9 years. Patients with osteoporosis (trabecular bone density of the radius ~2.5 SD of the value of healthy 45-54-year-old normal women [10] ) or osteopenia (trabecular bone density of the radius 1-2.5 SD) without treatment underwent a follow-up measurement with high precise peripheral quantitative computed tomography (pQCT) [11] not earlier than 4 months after the first measurement. If a trabecular bone loss in the radius of 3% [12] (Fig. I) or more, calculated for 1 year was found, the patients were defined as "fast losers" and admitted to the study. They underwent a treatment with active vitamin D metabolites for 8-18 months. The patients underwent a third pQCT measurement not earlier than 8 months after the treatment was started. The measured difference in percentage was again calculated for I year. Either 0.5 J,1g calcitriol or 1 J,1g alfacalc idol was given daily.
Bone Densitometry
The measurements were performed with the pQCT DENSISCAN 1000 (Scanco, Zurich, Switzerland) [13, 14] , which has a reproducibility in mixed collectives of 0.3% [15] . The measuring procedure can be characterized as foHows. The patient's arm is posi- The distribution was bimodal and shows a minimum at 3%. This value is taken to separate fast bone losers from slow bone losers. tioned in a radiolucent cast which enables comfortable immobilization during the measuring process and allows reproducible orientation of the bone axis relative to the measuring plane. The measuring system-a special-purpose CT instrument for low-dose bone densitometry-provides a digital radiogram as a positioning aid for the examination site. The examination site in the ultradistal radius is then converted with a stack of 10 tomograms (slice thickness I mm, interslice distance 1.5 mm), and the average bone density over core volume (D 50) is calculated. This value corresponds to the trabecular bone density (mg/cm 3 ). After the three measurements, the bone volume common to all examinations of a patient is determined. Then the percentage of trabecular bone density changes in the radius are evaluated. The radiation dose per examination is only 0.1 mSv [12] . Cortical bone density is measured in the diaphysis from six tomograms (P < 100).
Statistical Analysis
The mean and SEM were calculated for the changes in trabecular and cortical bone denisty in percentage between the first and the second as well as between the second and third pQCT. These changes before and after treatment were analyzed with the paired Student's t-test. Table 1 summarizes the measured initial values and changes in percentage of the trabecular bone density before and after treatment. Table 2 shows the same values for the cortical bone. The initial value found in the first pQCT for trabecular bone density in the distal radius for all patients was 133.61 ± 11.86 mg/cm 3 (mean ± SEM). This is clearly below the bone density of healthy women 45-54 years old (255 mg/cm 3 ).
Results
After 10.13 ± 0.87 (mean ± SEM) months, a second pQCT was performed which showed a trabecular bone loss Values are mean ± SEM After treatment
in the peripheral radius of -6.61 ± 0.52% (mean ± SEM) and the cortical bone loss of -1.76 ± 0.34% (mean ± SEM) calculated for I year. After undergoing a treatment with either calcitriol or alfacalcidol for 12.13 ± 0.43 (mean ± SEM) months, the third pQCT was performed. It showed a trabecular bone gain of + 0.01 ± 0.59% (mean ± SEM) and a reduced loss of cortical bone of -0.24 ± 0.39% (mean ± SEM) calculated for I year (Figs. 2 and 3 ). Analyzing the values before and after treatment with the paired Student's t-test, a highly significant difference for trabecular bone could be found (P < 0.001). For cortical bone, the difference was less significant (P < 0.05).
Discussion
The active vitamin D metabolites calcitriol (0.5 flg/daily) and alfacalcidol (I flg/daily) have been found to be highly effective in the treatment of fast trabecular bone loss in osteoporotic and osteopenic patients. We have shown that this treatment did not only stop the loss of trabecular bone density in the peripheral radius measured with the high precise pQCT but there was a gain of density in several patients. The cortical bone density loss was at least significantly reduced. The radius as a nonweight-bearing bone is less sensitive to changes in mobility habits of the patient. The trabecular bone density of the radius seems to be the most reliable parameter for an osteoporosis follow-up because it reflects the bone turnover. The therapy consisted of either 0.5 flg of calcitriol daily, the active kidney metabolite of I flg alfacalcidol daily. The la-hydroxyvitamin D3 (la-(OH)D 3 ) is a pro-drug which is hydroxylated in the liver and bone into the active 1,25-dihydroxyvitamin D3 [3] . The dose of 0.5 flg calcitriol is equivalent to 1 flg alfacalcidol.
Vitamin D metabolites have been proven in this study to be antiresorptive, active agents in fast-losing osteoporosis. The mechanisms through which this occurs are reported to be (I) increasing the active vitamin D metabolites in the before treatment after treatment (11'9 A1focalcidol, 0.5 1'9 Calcitriol)
0.01 before treatment ofter treatment (11'9 Alfocalcidal, 0.5 1'9 Calcitriol) serum and the bone that are low due to a lower production in the kidney (lack of la-hydroxylase) and the bone [16] ; (2) facing the vitamin D resistance due to the lack of 1,25(OH)zD3 receptors in the intestine and the bone [17, 18] ; (3) facing the effect of the senile secondary hyperparathyroidism [19] due to the increase of cell number in the parathyroid gland [20] ; (4) reducing the increase of cytokines (IL-l, IL-6) induced by the postmenopausal estrogen 117 deficiency [21, 22] . In addition, the increase of PTH causes decreased coupled bone formation [23] which is due to changes of the insulin-like growth factor (IGF) system. PTH induces a higher production of binding protein 4 (IGFBP4) which neutralizes the anabolic effect of IGF. Active vitamin D metabolites can replace the currently used antiresorptive agents such as estrogens, calcitonin, and bisphosphonates thanks to their high efficacy, low toxicity, and less side effects [24] . In the study's collective, no severe hypercalcemia was found; the highest measured value under treatment was 2.48 mmol/liter (upper normal value 2.42 mmollliter). This is due to the controlled amount of oral calcium intake which is reported to be 600-800 mg per day [25] . Moreover, a considerable number of our patients have reported an increase in general well-being and a decrease of pain. None of the patients suffered severe dizziness. Only a few patients have reported intestinal problems such as stomach pain or diarrhea. These problems could always be solved by interrupting the treatment for about 2 weeks and restarting it in splitted dose of, e.g., two times 0.25 ,..,.,g calcitriol 2x/day.
